ARPO Aerpio Pharmaceuticals Inc

EQS-News: Sentis Capital: Meyer Burger on the verge of decisive course changes

EQS Group-News: Dynamics Group AG / Key word(s): Miscellaneous
Sentis Capital: Meyer Burger on the verge of decisive course changes

06.12.2018 / 17:45


PRESS RELEASE
Balzers, December 6, 2018

Sentis Capital sees Meyer Burger on the verge of decisive course changes

- In-house production of heterojunction (HJT) and tandem solar cells as a huge opportunity.

- The Board of Directors must examine all strategic options, including financing through the
capital market.

- Meyer Burger must gain new credibility by renewing its Board of Directors.


We have learned from Meyer Burger (SIX Swiss Exchange: MBTN) that ways to commercialize the high technology portfolio, especially for processes and equipment for manufacturing heterojunction (HJT) and tandem solar cells are being evaluated. A Swiss investment bank supports Meyer Burger in this process.

Sentis Capital PCC, as the largest single shareholder of Meyer Burger Technology AG (6.14% stake in share capital), welcomes this approach. Based on its own analyses, Sentis Capital is also convinced that Meyer Burger has a significant competitive advantage in these technologies.

Currently, the difficult market environment prevents leading manufacturers of solar modules from relying on HJT despite clear advantages. The competitive advantage at the level of gross profit for the producer, is around USD 7ct per watt peak, according to statements by Meyer Burger. However, the complete transition of existing production lines involves high investments by the customers with the simultaneous risk that the competitive advantage will disappear relatively quickly, unless the customer negotiates some form of exclusivity with Meyer Burger.

It is important to note that Meyer Burger has the necessary experience for its own production: Since 2013, the company has been producing HJT solar cells in its own mass production facility in Hohenstein-Ernstthal (Germany). Therefore, the question arises why Meyer Burger is not complementing its business model and using the competitive advantage of net USD 7ct per watt peak for itself? Meyer Burger would thus be able to protect its own technology and benefit directly from future improvements in efficiency and throughput of the equipment.

Therefore, Meyer Burger would follow the extremely successful strategy of First Solar (USA), which, by protecting its own technology and the exclusive ties with its equipment manufacturer in Germany, has achieved a leading position in thin-film technology and created value for its shareholders over many years.

As Meyer Burger is currently not in a position to finance a production of at least 5 to 10 GW from its own funds, in our opinion this would have to be done through a capital increase on the capital market or through a strategic partner who is prepared to pay a corresponding premium.

As Meyer Burger's largest single shareholder, we asked the Board of Directors to review all options in a competitive and global process and to choose the best option for the shareholder. There are indications that the Board of Directors is shying away from presenting the capital market with what may be the best option for financing its own production through the capital market.

Due to the extreme dimension of this decision for Meyer Burger, the Board of Directors should not decide on a strategic partnership before informing its own shareholders about the attractiveness and possibilities of an investment. Numerous previous examples prove that partnerships are attractive for the partner companies, but not for the company's own shareholders, who often cannot participate equally in the exploitable potential.

In its press release of 16 October, Meyer Burger already announced that changes would be made at the management and board level. We assume that these adjustments will be made promptly in order to enable the new Board of Directors to credibly present this strategic change to the capital market.


Anton Karl, Mark Kerekes,
Members of the Board Sentis Capital PCC, a subsidiary of Elbogross SA


Further information:
Dynamics Group AG
Andreas Durisch
Phone: 2
E-mail:


About Sentis Capital
Sentis Capital PCC, Balzers, is a subsidiary of Elbogross SA and is responsible for the treasury management and capital market investment of the entire group. Elbogross SA is a holding company based in Switzerland and wholly owned by Petr Kondrashev, resident in Lower Austria. The divisions of Elbogross SA originate from a former industrial conglomerate in the mineral fertilizer sector. Today, the focus of its activities is on corporate investments and real estate.


Additional features:

Document:
Document title: Sentis_MM_MBTN_6.12.2018


End of Corporate News


755313  06.12.2018 

fncls.ssp?fn=show_t_gif&application_id=755313&application_name=news&site_id=research_pool
EN
06/12/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

 PRESS RELEASE

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

 PRESS RELEASE

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

 PRESS RELEASE

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

 PRESS RELEASE

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch